MOMA Therapeutics

Vigil will use the Series A funds to progress its lead pipeline candidate, a monoclonal antibody TREM2 agonist, through Phase 1 studies, advance their small molecule TREM2 agonist to IND, as well as pursue additional assets to grow the pipeline and increase the body of data supporting microglia biology as an important therapeutic pathway.

Momenta Pharmaceuticals is a biotechnology company that specializes in the detailed structural analysis and design of complex sugars for the development of improved versions of existing drugs, the development of novel drugs and the discovery of new biological processes. The company also utilizes its ability to sequence the molecular structure of sugars to create technology-enabled generic versions of complex sugar-based products. Its advanced product candidate, M-Enoxaparin, is designed to be a technology-enabled generic version of Lovenox, an often-prescribed low molecular weight heparin. The company s technology provides a better understanding of the roles that sugars play in cellular function, disease and drug action. Momenta Pharmaceuticals is headquartered in Cambridge, Mass.

Orbital Therapeutics, based in Cambridge, MA, is dedicated to advancing RNA medicines aimed at expanding access to innovative therapies for patients with various diseases. Their cutting-edge platform integrates RNA discovery and design, focusing on immune reprogramming to help restore health by delivering precise molecular instructions directly to immune cells. The company emphasizes a culture of collaboration and has assembled a team experienced in transitioning medicines from concept to clinical application. Through their comprehensive RNA platform, Orbital Therapeutics seeks to engineer durable therapies with the flexibility needed to effectively modulate disease outcomes. Generated from the website